Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (trading symbol: AKER) on July 10, 2020. The filing addresses corporate governance matters related to the scheduling of the company's 2020 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly procedural and contains no financial performance data.
Material Changes
The primary material change reported is the rescheduling of the 2020 Annual Meeting of Stockholders:
- New Meeting Date: August 27, 2020.
- Record Date: July 10, 2020.
- Reason for Disclosure: The meeting date was changed by more than 30 days from the anniversary of the 2019 Annual Meeting, triggering a requirement to disclose the deadline for shareholder proposals and director nominations.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, or specific risk factors. It outlines the procedural deadlines for shareholders:
- Proposal Deadline: Stockholder proposals or nominations for inclusion in the proxy statement must be received by 5:00 p.m. Eastern Time on July 23, 2020.
- Compliance: Proposals must comply with Rule 14a-8 under the Exchange Act and the Company's Bylaws.
Key Facts for Investor Verification
- Verify the new Annual Meeting date of August 27, 2020, against the company's investor relations calendar.
- Confirm the July 23, 2020, deadline for submitting shareholder proposals if intending to participate in the proxy process.
- Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial data.